Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand
Richard Jaine, Giorgi Kvizhinadze, Nisha Nair, Tony Blakely
Lung Cancer | ELSEVIER IRELAND LTD | Published : 2020
OBJECTIVES: The cost-effectiveness of low-dose computed tomography (LDCT) screening for lung cancer is uncertain. This study estimated the health gains, costs (net health system, and including 'unrelated') and cost-effectiveness of biennial LDCT screening among 55-74 years olds with a smoking history of at least 30 pack years, and (if a former smoker) having quit within last 15 years, in New Zealand. METHODS: We used a macrosimulation stage shift model with New Zealand-specific lung cancer incidence rates and intervention parameters from the National Lung Screening Trial, a health system perspective, and a lifetime horizon for quality-adjusted life-years (QALYs) and costs discounted at 3% pe..View full abstract
Awarded by Health Research Council of New Zealand
This work was supported by the Health Research Council of New Zealand, grant number 10/248.